Financial Health Assessment: CETA FORM LIMITED

1. Financial Health Score: C+

Explanation: The patient is currently stable and ambulatory, but exhibiting a concerning downward trend in overall vitality. While the business is solvent and has no immediate risk of cardiac arrest (insolvency), it is suffering from a chronic loss of reserves. Having recovered from a near-fatal event in 2019, the company is now showing symptoms of a slow bleed, with equity eroding year over year since 2021.

2. Key Vital Signs

• Pulse (Liquidity Ratio): 1.13x (Current Assets £20,710 / Current Liabilities £18,237). The patient has a pulse, but it is weak. A ratio of 1.13 means the business has just enough liquid assets to cover its short-term debts, leaving virtually no margin for error.
• Blood Pressure (Leverage): Elevated. Total liabilities (£18,237) outweigh the total equity/shareholders' funds (£14,447), resulting in a debt-to-equity ratio of approximately 1.26. The business is highly reliant on creditor financing to fund its operations, which keeps blood pressure dangerously high.
• Weight (Asset Base): £37,594. This is a micro-entity, meaning it is naturally slight in stature. However, the composition is balanced between fixed assets (£16,884) and current assets (£20,710).
• Immune System (Equity Buffer): Thinning. Net assets have dropped from a recent peak of £18,559 in 2021 to £14,447 in 2025. The company's financial immune system is weakening, leaving it less protected against external economic shocks.

3. Diagnosis: Chronic Equity Erosion with Acute Liquidity Pressure

Based on the symptoms presented in the financial history, the diagnosis is a business that is slowly bleeding out its retained earnings, likely operating on razor-thin margins or distributing more capital than it generates.

Symptoms Analysis: * The Slow Bleed: The most alarming symptom is the steady decline in shareholders' funds over the last four years (from £18,559 down to £14,447). In the absence of detailed P&L data (due to micro-entity filing exemptions), shrinking equity is a classic symptom of annual trading losses or excessive director dividends stripping the business of its vital fluids. * Rising Short-Term Debts: Current liabilities have surged by 30% in the last year alone (from £13,944 to £18,237). This suggests the business is stretching creditor payments or taking on more short-term debt just to maintain its current level of circulation. * Historical Resilience vs. Current Relapse: It is worth noting that this patient has survived a critical emergency before. In 2019, the business was in negative equity (-£4,598)—technically insolvent on paper. Management successfully nursed it back to health by 2021, proving they have the capability to turnaround distress. However, the current trajectory looks like a relapse of the same underlying condition.

4. Prognosis: Cautiously Guarded

The future outlook is cautiously guarded. The business is not currently at risk of sudden collapse, but if the current rate of equity erosion continues, CETA FORM LIMITED will deplete its financial reserves within the next 7 to 8 years, potentially returning to the critical insolvency zone of 2019. As a wholesale hardware business heavily exposed to economic cycles and supply chain costs, the thinning equity buffer leaves it highly vulnerable to external shocks.

5. Recommendations: Prescribed Treatment Plan

To stabilize the patient and restore long-term financial wellness, the following interventions are recommended:

1. Stop the Bleeding (Cost & Margin Control): Conduct an immediate review of pricing strategies and overheads. In the wholesale sector, margins can easily slip. Ensure every sale is generating a healthy gross profit to stem the outflow of equity.
2. Improve Circulation (Cash Flow Management): With a current ratio of just 1.13, cash flow is sluggish. Tighten credit control procedures—chase outstanding invoices promptly and consider offering early payment discounts to clients to get cash into the business faster.
3. Reduce Blood Pressure (Debt Restructuring): The reliance on short-term creditors is putting immense pressure on the business. Explore whether some of the £18k in current liabilities can be restructured into longer-term financing, or negotiate extended payment terms with suppliers to ease the immediate pressure.
4. Nutritional Supplements (Capital Injection): If the slow bleed is partially caused by director drawings, the directors (Mr. and Xxxxxx Xxxxxxxxname shown to subscribers) should evaluate whether the business can sustain current levels of withdrawal. If the business is making losses, a temporary halt on dividends, or even a modest capital injection from the directors, would act as a much-needed transfusion to rebuild the equity buffer.

Names of the people mentioned are shown to subscribers. See subscription